Ang-2 expression in tumor cells decreases after lenvatinib treatment, as anti-VEGF treatment is thought to reduce Ang-2 expression in tumor cells by normalizing tumor blood vessels and reducing hypoxia in the tumor microenvironment [6, 7]. This evidence concerns the gene VEGFA and neoplasm.